205 related articles for article (PubMed ID: 37070927)
1. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
3. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
4. Progress and challenges in RET-targeted cancer therapy.
Hu X; Khatri U; Shen T; Wu J
Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
6. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
Shen T; Hu X; Liu X; Subbiah V; Mooers BHM; Wu J
NPJ Precis Oncol; 2021 Jun; 5(1):48. PubMed ID: 34099825
[TBL] [Abstract][Full Text] [Related]
7. RET kinase alterations in targeted cancer therapy.
Liu X; Hu X; Shen T; Li Q; Mooers BHM; Wu J
Cancer Drug Resist; 2020; 3(3):472-481. PubMed ID: 35582449
[TBL] [Abstract][Full Text] [Related]
8. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Fancelli S; Caliman E; Mazzoni F; Brugia M; Castiglione F; Voltolini L; Pillozzi S; Antonuzzo L
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806299
[TBL] [Abstract][Full Text] [Related]
9. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
[TBL] [Abstract][Full Text] [Related]
10. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
[TBL] [Abstract][Full Text] [Related]
11. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
12. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
[TBL] [Abstract][Full Text] [Related]
15. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
[TBL] [Abstract][Full Text] [Related]
16. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
17. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract][Full Text] [Related]
18. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
19. RET kinase inhibitors for
Vodopivec DM; Hu MI
Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
[TBL] [Abstract][Full Text] [Related]
20. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
